The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial
Background: SAHA (Seborrhea, Acne, Hirsutism and Androgenetic Alopecia) syndrome is a dermatologic disorder, with variant response to treatment. Triad of cutaneous hyperandrogenism included nodulocystic or severe acne, female pattern hair loss and hirsutism. Aim: The aim of this study is to compare...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
| Series: | Advanced Biomedical Research |
| Subjects: | |
| Online Access: | http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=262;epage=262;aulast=Faghihi |
| _version_ | 1818430981448663040 |
|---|---|
| author | Gita Faghihi Kioumars Jamshidi Nabet Tajmirriahi Bahareh Abtahi-Naeini Mohamadali Nilforoshzadeh Mohamadreza Radan Sayed Mohsen Hosseini |
| author_facet | Gita Faghihi Kioumars Jamshidi Nabet Tajmirriahi Bahareh Abtahi-Naeini Mohamadali Nilforoshzadeh Mohamadreza Radan Sayed Mohsen Hosseini |
| author_sort | Gita Faghihi |
| collection | DOAJ |
| description | Background: SAHA (Seborrhea, Acne, Hirsutism and Androgenetic Alopecia) syndrome is a dermatologic disorder, with variant response to treatment. Triad of cutaneous hyperandrogenism included nodulocystic or severe acne, female pattern hair loss and hirsutism.
Aim: The aim of this study is to compare the effectiveness of isotretinoin and cyproterone compound in the treatment of nodulocystic acne, in patients with SAHA syndrome or triad of cutaneous hyperandrogenism.
Materials and Methods: 30 female patients with SAHA syndrome were divided randomly into two groups. Group A was treated with cyproterone compound from day 5 of menstrual cycle onwards for 3 weeks and a week without it and group B received isotretinoin, with a dose of 0.75 mg/kg per day from the beginning of menses onwards for 4 months. The results were evaluated by a blind dermatologist using Acne Severity Index (ASI) score at baseline and monthly for 4 months.
Results: Despite a continuous reduction in ASI score in both the groups, according to both physician (P = 0.63) and patient (P = 0.25) assessment, cyproterone compound was not statistically more effective than conventional treatment of nodulocystic acne at the end of the study. Side-effects were reported in patients in both groups, generally being mild and tolerable except in two subjects.
Conclusion: This study indicates that cyproterone compound is not superior to isotretinoin in the treatment of nodulocystic acne in patient with SAHA syndrome or triad of cutaneous hyperandrogenism. Indeed, other studies are needed to evaluate the effect of cyproterone compound (regardless of androgen level) and isotretinoin in subjects with only nodulocystic acne. |
| first_indexed | 2024-12-14T15:42:03Z |
| format | Article |
| id | doaj.art-f401dfa49b0a432bb7a7e9d2e15276fb |
| institution | Directory Open Access Journal |
| issn | 2277-9175 2277-9175 |
| language | English |
| last_indexed | 2024-12-14T15:42:03Z |
| publishDate | 2014-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Advanced Biomedical Research |
| spelling | doaj.art-f401dfa49b0a432bb7a7e9d2e15276fb2022-12-21T22:55:36ZengWolters Kluwer Medknow PublicationsAdvanced Biomedical Research2277-91752277-91752014-01-013126226210.4103/2277-9175.148236The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trialGita FaghihiKioumars JamshidiNabet TajmirriahiBahareh Abtahi-NaeiniMohamadali NilforoshzadehMohamadreza RadanSayed Mohsen HosseiniBackground: SAHA (Seborrhea, Acne, Hirsutism and Androgenetic Alopecia) syndrome is a dermatologic disorder, with variant response to treatment. Triad of cutaneous hyperandrogenism included nodulocystic or severe acne, female pattern hair loss and hirsutism. Aim: The aim of this study is to compare the effectiveness of isotretinoin and cyproterone compound in the treatment of nodulocystic acne, in patients with SAHA syndrome or triad of cutaneous hyperandrogenism. Materials and Methods: 30 female patients with SAHA syndrome were divided randomly into two groups. Group A was treated with cyproterone compound from day 5 of menstrual cycle onwards for 3 weeks and a week without it and group B received isotretinoin, with a dose of 0.75 mg/kg per day from the beginning of menses onwards for 4 months. The results were evaluated by a blind dermatologist using Acne Severity Index (ASI) score at baseline and monthly for 4 months. Results: Despite a continuous reduction in ASI score in both the groups, according to both physician (P = 0.63) and patient (P = 0.25) assessment, cyproterone compound was not statistically more effective than conventional treatment of nodulocystic acne at the end of the study. Side-effects were reported in patients in both groups, generally being mild and tolerable except in two subjects. Conclusion: This study indicates that cyproterone compound is not superior to isotretinoin in the treatment of nodulocystic acne in patient with SAHA syndrome or triad of cutaneous hyperandrogenism. Indeed, other studies are needed to evaluate the effect of cyproterone compound (regardless of androgen level) and isotretinoin in subjects with only nodulocystic acne.http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=262;epage=262;aulast=FaghihiAcnecyproterone compoundhyperandrogenismisotretinoinSAHA |
| spellingShingle | Gita Faghihi Kioumars Jamshidi Nabet Tajmirriahi Bahareh Abtahi-Naeini Mohamadali Nilforoshzadeh Mohamadreza Radan Sayed Mohsen Hosseini The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial Advanced Biomedical Research Acne cyproterone compound hyperandrogenism isotretinoin SAHA |
| title | The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial |
| title_full | The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial |
| title_fullStr | The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial |
| title_full_unstemmed | The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial |
| title_short | The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial |
| title_sort | efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism a randomized clinical trial |
| topic | Acne cyproterone compound hyperandrogenism isotretinoin SAHA |
| url | http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=262;epage=262;aulast=Faghihi |
| work_keys_str_mv | AT gitafaghihi theefficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT kioumarsjamshidi theefficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT nabettajmirriahi theefficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT baharehabtahinaeini theefficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT mohamadalinilforoshzadeh theefficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT mohamadrezaradan theefficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT sayedmohsenhosseini theefficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT gitafaghihi efficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT kioumarsjamshidi efficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT nabettajmirriahi efficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT baharehabtahinaeini efficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT mohamadalinilforoshzadeh efficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT mohamadrezaradan efficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial AT sayedmohsenhosseini efficacyoforalisotretinoinversuscyproteronecompoundinfemalepatientswithacneandthetriadofcutaneoushyperandrogenismarandomizedclinicaltrial |